Li Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Li Chen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Mia Yang Ang
Department of Biomedical Sciences, Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Sunway City, Petaling Jaya 47500, Selangor, Malaysia
6 shared publications - Siew Woh Choo
Zhejiang-Malaysia Joint Laboratory for Rare Medicinal Resources, Wenzhou-Kean University, 88 Daxue Road, Ouhai, Wenzhou 325060, China
6 shared publications - Lanni Song
Zhejiang-Malaysia Joint Laboratory for Rare Medicinal Resources, Wenzhou-Kean University, 88 Daxue Road, Ouhai, Wenzhou 325060, China
5 shared publications - Leonard Lipovich
Zhejiang-Malaysia Joint Laboratory for Rare Medicinal Resources, Wenzhou-Kean University, 88 Daxue Road, Ouhai, Wenzhou 325060, China
5 shared publications - Chunting Yang
Department of Biology, College of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou 325035, China
1 shared publication - Dale King
College of Arts & Sciences, American University of Iraq, Baghdad, Airport Road, Baghdad 10023, Iraq
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19  (9) , 1465
Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making
Background/Objectives: Antimicrobial resistance has renewed interest in live therapeutic phages, including engineered candidates and defined phage cocktails, as antibacterial strategies. However, clinical translation requires evidence extending beyond phage isolation and computational prediction. This review examines how phage genomics and bioinformatics can support phage-based antibacterial development while remaining aligned with pharmaceutical requirements for safety, quality, pharmacology, and clinical validation. Methods: This narrative review synthesizes the literature on the generation, interpretation, and experimental validation of genomic and bioinformatic evidence for live therapeutic phages. Representative approaches for viral identification, genome-quality assessment, annotation, comparative genomics, lytic–temperate lifestyle classification, host prediction, receptor analysis, antiphage-defence profiling, and artificial-intelligence-assisted prioritization were evaluated according to their outputs, principal failure modes, validation requirements, and supported development decisions. Results: Current tools address distinct analytical tasks. Examples include VIBRANT and geNomad for viral identification, CheckV and PhageTerm for genome-quality and termini assessment, Pharokka, PHANOTATE, and PHROGs for gene prediction and annotation, PhageAI, BACPHLIP, and PhaTYP for lytic–temperate lifestyle prediction, iPHoP and CRISPR spacer matching for host prioritization, and PADLOC and DefenseFinder for bacterial defence profiling. Their outputs differ in taxonomic resolution, reference coverage, training-data dependence, and biological interpretation. The review maps these outputs to proportionate validation requirements while integrating formulation and PK/PD context, sequence-to-product traceability, intellectual-property documentation, minimum-information reporting, and resistance-responsive redesign. Conclusions: This review presents a practical sequence-to-product framework for interpreting contemporary phage-bioinformatics methods. By separating computational discovery from isolate-level activity, product quality, pharmacological evidence, and clinical monitoring, it clarifies the decisions supported at each stage and the additional evidence required before candidate progression, product use, or redesign.
- 16 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19  (9) , 1465
Open AccessPhage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making
Background/Objectives: Antimicrobial resistance has renewed interest in live therapeutic phages, including engineered candidates and defined phage cocktails, as antibacterial strategies. However, clinical translation requires evidence extending beyond phage isolation and computational prediction. This review examines how phage genomics and bioinformatics can support phage-based antibacterial development while remaining aligned with pharmaceutical requirements for safety, quality, pharmacology, and clinical validation. Methods: This narrative review synthesizes the literature on the generation, interpretation, and experimental validation of genomic and bioinformatic evidence for live therapeutic phages. Representative approaches for viral identification, genome-quality assessment, annotation, comparative genomics, lytic–temperate lifestyle classification, host prediction, receptor analysis, antiphage-defence profiling, and artificial-intelligence-assisted prioritization were evaluated according to their outputs, principal failure modes, validation requirements, and supported development decisions. Results: Current tools address distinct analytical tasks. Examples include VIBRANT and geNomad for viral identification, CheckV and PhageTerm for genome-quality and termini assessment, Pharokka, PHANOTATE, and PHROGs for gene prediction and annotation, PhageAI, BACPHLIP, and PhaTYP for lytic–temperate lifestyle prediction, iPHoP and CRISPR spacer matching for host prioritization, and PADLOC and DefenseFinder for bacterial defence profiling. Their outputs differ in taxonomic resolution, reference coverage, training-data dependence, and biological interpretation. The review maps these outputs to proportionate validation requirements while integrating formulation and PK/PD context, sequence-to-product traceability, intellectual-property documentation, minimum-information reporting, and resistance-responsive redesign. Conclusions: This review presents a practical sequence-to-product framework for interpreting contemporary phage-bioinformatics methods. By separating computational discovery from isolate-level activity, product quality, pharmacological evidence, and clinical monitoring, it clarifies the decisions supported at each stage and the additional evidence required before candidate progression, product use, or redesign.
- Open Access
Trustworthy Agentic AI in Bioinformatics: From Workflow Automation to Traceable and Validated Biological Inference
Agentic artificial intelligence is extending bioinformatics beyond conversational assistance by enabling systems to select tools, execute code, revise analytical plans, and interpret biological data. These capabilities may accelerate research, but they also redistribute decisions that determine whether biological conclusions are valid. We conducted a targeted, structured PubMed search in July 2026 and identified 11 peer-reviewed agentic bioinformatics systems for descriptive review based on predefined eligibility criteria for analytical decision-making, tool or code execution, iterative evaluation, or coordinated agent activity. The evidence base covered single-cell transcriptomics, microbial genomics, cancer genomics, and omics applications, together with methodological literature on reproducibility and biological validation. We examined how current systems report delegated authority, provenance, validation, evidence, abstention, and human oversight. Existing platforms implement safeguards such as sandboxed execution, restricted commands, interaction logs, evidence identifiers, automated checks, critic agents, quality scores, and expert assessment. However, published reports rarely provide a connected account linking the original biological question to samples, reference resources, analytical decisions, computational actions, statistical results, supporting evidence, validation outcomes, and final claims. We distinguish inherited bioinformatics errors, errors amplified through autonomous action, and emergent failures arising from memory, retrieval, tool interaction, or agent coordination. We further propose a multidimensional decision-rights profile, consequence-sensitive validation gates, and a claim-to-evidence provenance architecture organized through the Traceable History of Research Evidence, Agent Actions, and Decisions in Bioinformatics (THREAD-Bio) framework. Illustrative cases show that technically successful execution may still support misleading inference. Trustworthy agentic bioinformatics therefore requires claims to remain reconstructible, challengeable, validated, and proportionate to the evidence.
Open AccessTrustworthy Agentic AI in Bioinformatics: From Workflow Automation to Traceable and Validated Biological Inference
Agentic artificial intelligence is extending bioinformatics beyond conversational assistance by enabling systems to select tools, execute code, revise analytical plans, and interpret biological data. These capabilities may accelerate research, but they also redistribute decisions that determine whether biological conclusions are valid. We conducted a targeted, structured PubMed search in July 2026 and identified 11 peer-reviewed agentic bioinformatics systems for descriptive review based on predefined eligibility criteria for analytical decision-making, tool or code execution, iterative evaluation, or coordinated agent activity. The evidence base covered single-cell transcriptomics, microbial genomics, cancer genomics, and omics applications, together with methodological literature on reproducibility and biological validation. We examined how current systems report delegated authority, provenance, validation, evidence, abstention, and human oversight. Existing platforms implement safeguards such as sandboxed execution, restricted commands, interaction logs, evidence identifiers, automated checks, critic agents, quality scores, and expert assessment. However, published reports rarely provide a connected account linking the original biological question to samples, reference resources, analytical decisions, computational actions, statistical results, supporting evidence, validation outcomes, and final claims. We distinguish inherited bioinformatics errors, errors amplified through autonomous action, and emergent failures arising from memory, retrieval, tool interaction, or agent coordination. We further propose a multidimensional decision-rights profile, consequence-sensitive validation gates, and a claim-to-evidence provenance architecture organized through the Traceable History of Research Evidence, Agent Actions, and Decisions in Bioinformatics (THREAD-Bio) framework. Illustrative cases show that technically successful execution may still support misleading inference. Trustworthy agentic bioinformatics therefore requires claims to remain reconstructible, challengeable, validated, and proportionate to the evidence.
- Open Access
- 4 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (15) , 7015
Functional Annotation of GWAS Loci Using Public Transcriptome and Epigenome Datasets Reveals Non-Coding Genes and Regulatory Elements Which May Contribute to BMI
Genome-wide association studies have identified numerous genetic variants statistically significantly associated with body mass index (BMI). However, the functional mechanisms underlying most associations between single nucleotide polymorphisms (SNPs) in non-coding regions and BMI remain poorly understood. Here, we implemented an integrative 7-criterion quantitative scoring system (gene localization, histone modifications, transcription factor binding sites (TFBS), SNP clouds, tissue expression patterns, evolutionary conservation, and COVID-19 associations) to prioritize putative functional loci among 94 BMI-associated SNPs. Six SNPs resided within long non-coding RNA (lncRNA) genes: rs2245368 (exonic, DTX2P1-UPK3BP1-PMS2P11), rs2033529 (exonic, LINC00951), rs2836754 (intronic, ETS2-AS1), rs2815752 (intronic, LINC02796), rs17203016 (intronic, MYOSLID-AS1), and rs7239883 (intronic, LINC00907). We prioritized them because they are located within lncRNA gene bodies and therefore showed stronger functional support compared to other variants which only had non-coding regulatory elements in their vicinity. Notably, rs1928295 exhibited strong GATA2 binding evidence, while rs13201877 had extensive transcription factor occupancy (64 factors). Multiple variants demonstrated putative regulatory potential through epigenomic evidence, including DNase I hypersensitivity and cell-type-specific chromatin accessibility. We show that most BMI risk alleles are not human-specific and are conserved across primates. Our findings suggest putative candidate non-coding regulatory elements in BMI and provide prioritized obesity-associated non-coding variants for functional validations.
- 4 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27  (15) , 7015
Open AccessFunctional Annotation of GWAS Loci Using Public Transcriptome and Epigenome Datasets Reveals Non-Coding Genes and Regulatory Elements Which May Contribute to BMI
Genome-wide association studies have identified numerous genetic variants statistically significantly associated with body mass index (BMI). However, the functional mechanisms underlying most associations between single nucleotide polymorphisms (SNPs) in non-coding regions and BMI remain poorly understood. Here, we implemented an integrative 7-criterion quantitative scoring system (gene localization, histone modifications, transcription factor binding sites (TFBS), SNP clouds, tissue expression patterns, evolutionary conservation, and COVID-19 associations) to prioritize putative functional loci among 94 BMI-associated SNPs. Six SNPs resided within long non-coding RNA (lncRNA) genes: rs2245368 (exonic, DTX2P1-UPK3BP1-PMS2P11), rs2033529 (exonic, LINC00951), rs2836754 (intronic, ETS2-AS1), rs2815752 (intronic, LINC02796), rs17203016 (intronic, MYOSLID-AS1), and rs7239883 (intronic, LINC00907). We prioritized them because they are located within lncRNA gene bodies and therefore showed stronger functional support compared to other variants which only had non-coding regulatory elements in their vicinity. Notably, rs1928295 exhibited strong GATA2 binding evidence, while rs13201877 had extensive transcription factor occupancy (64 factors). Multiple variants demonstrated putative regulatory potential through epigenomic evidence, including DNase I hypersensitivity and cell-type-specific chromatin accessibility. We show that most BMI risk alleles are not human-specific and are conserved across primates. Our findings suggest putative candidate non-coding regulatory elements in BMI and provide prioritized obesity-associated non-coding variants for functional validations.
- Open Access
- 31 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14  (8) , 1722
AI-Guided Long Non-Coding RNA Target Discovery for Precision Medicine: Integrating GWAS, Multi-Omics, Experimental Validation, and RNA Therapeutics
Background/Objectives: Precision medicine requires translation of genetic and molecular variation into clinically actionable therapeutic targets. However, many disease-associated signals identified by genome-wide association studies (GWAS) reside in non-coding regulatory regions, making biological interpretation and therapeutic prioritization difficult. Long non-coding RNAs (lncRNAs) are regulatory molecules with growing relevance to disease mechanisms, biomarker discovery, patient stratification, and RNA-based therapeutics. This review presents a translational framework for AI-guided lncRNA target discovery, linking non-coding genetic signals to experimental validation and clinical implementation. Methods: This narrative review synthesizes literature on GWAS interpretation, quantitative trait loci analysis, epigenomic annotation, single-cell and spatial transcriptomics, multi-omics integration, artificial intelligence and machine learning, experimental validation, RNA therapeutic modality selection, delivery assessment, safety evaluation, and biomarker-informed precision medicine. Results: Genetic and multi-omics data can nominate disease-relevant lncRNAs, but no single evidence layer is sufficient to establish causality, mechanism, druggability, or clinical utility. AI can integrate heterogeneous biomedical datasets, rank candidate lncRNAs, detect regulatory patterns, and prioritize transcripts for validation. However, computational prediction should be interpreted as decision support rather than proof of therapeutic relevance. Candidate targets require disease-context expression validation, functional perturbation, mechanistic assessment, appropriate model systems, therapeutic modulation, delivery-feasibility assessment, safety evaluation, and patient-selection strategies. Conclusions: LncRNAs represent a promising but challenging therapeutic target class. A responsible translational pipeline should connect non-coding genetic evidence and multi-omics support with AI-guided prioritization, experimental validation, RNA therapeutic strategy selection, delivery assessment, safety evaluation, and clinical implementation. The framework defines qualification criteria and decision gates to reduce premature target claims during translational development.
- 31 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14  (8) , 1722
Open AccessAI-Guided Long Non-Coding RNA Target Discovery for Precision Medicine: Integrating GWAS, Multi-Omics, Experimental Validation, and RNA Therapeutics
Background/Objectives: Precision medicine requires translation of genetic and molecular variation into clinically actionable therapeutic targets. However, many disease-associated signals identified by genome-wide association studies (GWAS) reside in non-coding regulatory regions, making biological interpretation and therapeutic prioritization difficult. Long non-coding RNAs (lncRNAs) are regulatory molecules with growing relevance to disease mechanisms, biomarker discovery, patient stratification, and RNA-based therapeutics. This review presents a translational framework for AI-guided lncRNA target discovery, linking non-coding genetic signals to experimental validation and clinical implementation. Methods: This narrative review synthesizes literature on GWAS interpretation, quantitative trait loci analysis, epigenomic annotation, single-cell and spatial transcriptomics, multi-omics integration, artificial intelligence and machine learning, experimental validation, RNA therapeutic modality selection, delivery assessment, safety evaluation, and biomarker-informed precision medicine. Results: Genetic and multi-omics data can nominate disease-relevant lncRNAs, but no single evidence layer is sufficient to establish causality, mechanism, druggability, or clinical utility. AI can integrate heterogeneous biomedical datasets, rank candidate lncRNAs, detect regulatory patterns, and prioritize transcripts for validation. However, computational prediction should be interpreted as decision support rather than proof of therapeutic relevance. Candidate targets require disease-context expression validation, functional perturbation, mechanistic assessment, appropriate model systems, therapeutic modulation, delivery-feasibility assessment, safety evaluation, and patient-selection strategies. Conclusions: LncRNAs represent a promising but challenging therapeutic target class. A responsible translational pipeline should connect non-coding genetic evidence and multi-omics support with AI-guided prioritization, experimental validation, RNA therapeutic strategy selection, delivery assessment, safety evaluation, and clinical implementation. The framework defines qualification criteria and decision gates to reduce premature target claims during translational development.
- Open Access
- 14 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16  (7) , 1029
From GWAS Signals to Molecular Mechanisms: Explainable AI for Causal Gene Prioritization and Biomolecular Target Interpretation
Genome-wide association studies (GWAS) have identified thousands of loci associated with complex human diseases. However, the majority of the association signals reside in non-coding regions of the genome, and do not directly reveal the causal variant, effector gene, regulatory biomolecule, cell type, pathway, biomarker, or therapeutic target. Because many disease-associated variants act through non-coding regulatory mechanisms, post-GWAS interpretation increasingly depends on fine-mapping, expression quantitative trait loci, transcriptome-wide association studies, and functional evidence from single-cell multi-omics, network biology, and genetic target prioritization. Artificial intelligence can attempt to integrate these heterogeneous molecular evidence layers, but the resulting black-box prediction is insufficient when outputs cannot be biologically reproduced or experimentally tested. This review evaluates explainable artificial intelligence (XAI) as a framework for linking genetic association signals to molecular mechanisms and causal gene hypotheses. We argue that explainability is best treated as a biological requirement because useful models must expose evidence paths from significant disease-associated variants to regulatory elements, genes, transcripts, proteins, pathways, cell states, and therapeutic hypotheses. By emphasizing transparent evidence provenance, ancestry-aware interpretation, and functional validation, XAI can support the translation of GWAS signals into molecularly testable hypotheses for target prioritization and precision molecular medicine. The review focuses on the question of how to accomplish AI-accelerated functionalization of GWAS outputs across complex human diseases and traits.
- 14 July 2026
- Published by MDPI AG in Biomolecules
- Vol. 16  (7) , 1029
Open AccessFrom GWAS Signals to Molecular Mechanisms: Explainable AI for Causal Gene Prioritization and Biomolecular Target Interpretation
Genome-wide association studies (GWAS) have identified thousands of loci associated with complex human diseases. However, the majority of the association signals reside in non-coding regions of the genome, and do not directly reveal the causal variant, effector gene, regulatory biomolecule, cell type, pathway, biomarker, or therapeutic target. Because many disease-associated variants act through non-coding regulatory mechanisms, post-GWAS interpretation increasingly depends on fine-mapping, expression quantitative trait loci, transcriptome-wide association studies, and functional evidence from single-cell multi-omics, network biology, and genetic target prioritization. Artificial intelligence can attempt to integrate these heterogeneous molecular evidence layers, but the resulting black-box prediction is insufficient when outputs cannot be biologically reproduced or experimentally tested. This review evaluates explainable artificial intelligence (XAI) as a framework for linking genetic association signals to molecular mechanisms and causal gene hypotheses. We argue that explainability is best treated as a biological requirement because useful models must expose evidence paths from significant disease-associated variants to regulatory elements, genes, transcripts, proteins, pathways, cell states, and therapeutic hypotheses. By emphasizing transparent evidence provenance, ancestry-aware interpretation, and functional validation, XAI can support the translation of GWAS signals into molecularly testable hypotheses for target prioritization and precision molecular medicine. The review focuses on the question of how to accomplish AI-accelerated functionalization of GWAS outputs across complex human diseases and traits.
- Open Access
Responsible Use of Large Language Models in Microbial Genomics and Bioinformatics: A Life-Science Framework for Reliability, Reproducibility, and Risk-Aware Interpretation
Large language models (LLMs) are increasingly adopted in life-science research for scientific writing, coding, literature synthesis, workflow troubleshooting, and preliminary data interpretation. In microbial genomics and bioinformatics, their appeal is clear because researchers routinely integrate genome annotations, antimicrobial resistance profiles, virulence determinants, taxonomic assignments, microbiome outputs, workflow scripts, and primary literature. Yet this domain also highlights major risks, including hallucinated biological claims, inaccurate citations, irreproducible code, unsupported genotype-to-phenotype inference, and inappropriate clinical or public health framing. This narrative review examines responsible LLM use in microbial genomics as a representative life-science setting where interpretation depends on database provenance, validated workflows, expert assessment, and reproducible evidence chains. It considers applications in genome annotation, antimicrobial resistance interpretation, virulence analysis, microbiome and metagenomics workflows, coding support, and scientific writing. The review further presents MicrobeGuardGPT as a conceptual reliability framework for assessing LLM-assisted microbial genomics outputs before scientific, clinical, or public health use. By connecting task domains, evidence verification, expert validation, and reliability classification, the framework supports risk-aware LLM integration in bioinformatics. Responsible implementation will require domain-specific benchmarks, curated database linkage, transparent reporting, reproducible workflows, human oversight, and governance standards tailored to biological interpretation across research, diagnostic, surveillance, outbreak-response, educational, and translational contexts.
Open AccessResponsible Use of Large Language Models in Microbial Genomics and Bioinformatics: A Life-Science Framework for Reliability, Reproducibility, and Risk-Aware Interpretation
Large language models (LLMs) are increasingly adopted in life-science research for scientific writing, coding, literature synthesis, workflow troubleshooting, and preliminary data interpretation. In microbial genomics and bioinformatics, their appeal is clear because researchers routinely integrate genome annotations, antimicrobial resistance profiles, virulence determinants, taxonomic assignments, microbiome outputs, workflow scripts, and primary literature. Yet this domain also highlights major risks, including hallucinated biological claims, inaccurate citations, irreproducible code, unsupported genotype-to-phenotype inference, and inappropriate clinical or public health framing. This narrative review examines responsible LLM use in microbial genomics as a representative life-science setting where interpretation depends on database provenance, validated workflows, expert assessment, and reproducible evidence chains. It considers applications in genome annotation, antimicrobial resistance interpretation, virulence analysis, microbiome and metagenomics workflows, coding support, and scientific writing. The review further presents MicrobeGuardGPT as a conceptual reliability framework for assessing LLM-assisted microbial genomics outputs before scientific, clinical, or public health use. By connecting task domains, evidence verification, expert validation, and reliability classification, the framework supports risk-aware LLM integration in bioinformatics. Responsible implementation will require domain-specific benchmarks, curated database linkage, transparent reporting, reproducible workflows, human oversight, and governance standards tailored to biological interpretation across research, diagnostic, surveillance, outbreak-response, educational, and translational contexts.
- Open Access
Mechanistic Systems Biology of High-Salinity Fermented Seafood: Multi-Omics Integration for Microbial Safety and Quality Prediction
Foodborne diseases present a serious public health challenge, causing roughly 600 million illnesses and 420,000 deaths annually. A significant portion of this impact is felt in Asia, where traditional fermented and dry-salted seafood, such as katsuobushi, budu, and peda, are dietary staples. These products rely on diverse microbial communities that determine their final safety, flavor, texture, and shelf life. Historically, research has centered on lactic acid bacteria (LAB), yet the functional contributions of non-LAB halotolerant species, including genera like Tetragenococcus, Staphylococcus, and Bacillus, are functionally important in these high-salinity niches. This review evaluates the transition from basic taxonomic surveys to mechanistic multi-omics approaches, integrating genomics, transcriptomics, proteomics, and metabolomics to decode microbial functionality under selective environmental pressures. We discuss how genomic mining using platforms such as BAGEL4 and antiSMASH can uncover biosynthetic gene clusters and antimicrobial peptides, while CARD supports antimicrobial resistance monitoring. Transcriptomic analysis reveals microbial responses to osmotic stress, low water activity, and pH fluctuations, whereas proteomic profiling links gene expression to active enzymes, stress proteins, and functional biomarkers. Metabolomics captures the chemical outcomes of fermentation, including amino acids, volatile organic compounds, spoilage markers, and biogenic amines. By merging these high-dimensional datasets with artificial intelligence, researchers can move toward predictive modeling that distinguishes biological causation from simple correlation. This shift offers a strategy to improve the safety, consistency, and resilience of traditional high-salinity fermented seafood systems.
Open AccessMechanistic Systems Biology of High-Salinity Fermented Seafood: Multi-Omics Integration for Microbial Safety and Quality Prediction
Foodborne diseases present a serious public health challenge, causing roughly 600 million illnesses and 420,000 deaths annually. A significant portion of this impact is felt in Asia, where traditional fermented and dry-salted seafood, such as katsuobushi, budu, and peda, are dietary staples. These products rely on diverse microbial communities that determine their final safety, flavor, texture, and shelf life. Historically, research has centered on lactic acid bacteria (LAB), yet the functional contributions of non-LAB halotolerant species, including genera like Tetragenococcus, Staphylococcus, and Bacillus, are functionally important in these high-salinity niches. This review evaluates the transition from basic taxonomic surveys to mechanistic multi-omics approaches, integrating genomics, transcriptomics, proteomics, and metabolomics to decode microbial functionality under selective environmental pressures. We discuss how genomic mining using platforms such as BAGEL4 and antiSMASH can uncover biosynthetic gene clusters and antimicrobial peptides, while CARD supports antimicrobial resistance monitoring. Transcriptomic analysis reveals microbial responses to osmotic stress, low water activity, and pH fluctuations, whereas proteomic profiling links gene expression to active enzymes, stress proteins, and functional biomarkers. Metabolomics captures the chemical outcomes of fermentation, including amino acids, volatile organic compounds, spoilage markers, and biogenic amines. By merging these high-dimensional datasets with artificial intelligence, researchers can move toward predictive modeling that distinguishes biological causation from simple correlation. This shift offers a strategy to improve the safety, consistency, and resilience of traditional high-salinity fermented seafood systems.
- Open Access
Integrative Identification and Characterization of PCOS-Associated lncRNAs From the Interface of Genetic Association, Transcriptomics, and Gene Structure Evolution
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder and a leading cause of female infertility, with complex genetic, metabolic, and hormonal etiologies. Long non-coding RNAs (lncRNAs) have emerged as important regulators of diverse biological processes, yet their roles in PCOS remain underexplored. Here, we identified and characterized PCOS differentially expressed gene-associated lncRNAs (PDEGAL) with an integrative approach combining expression data, genetic association, and evolutionary analysis. Methods: Thirty-three PCOS-associated protein-coding genes were obtained from our prior study, and all their nearby and overlapping lncRNAs were annotated. These candidates were analyzed using UCSC Genome Browser-mapped annotations and datasets, including NCBI RefSeq, GENCODE, GTEx, GWAS SNPs, and conservation, as well as the FANTOM5 cap analysis of gene expression (CAGE) promoter data, to assess their expression, regulatory potential, genetic variant overlaps, and evolutionary conservation. Results: Twenty-three PDEGALs (18 antisense to, and 5 sharing bidirectional promoters with, known PCOS-associated protein-coding genes) were identified. 17 PDEGALs contained GWAS SNPs with statistically significant disease associations, 9 of which were associated with PCOS-related traits. 5 PDEGALs demonstrated expression in the KGN granulosa cell model of PCOS. Key gene structure element (KGSE) analysis revealed that most PDEGALs are primate-specific. Integrating four criteria—GTEx expression, GWAS SNPs, FANTOM promoterome, and KGSE conservation—highlighted HELLPAR as the only lncRNA fulfilling all four, while five others—PGR-AS1, MTOR-AS1, ENSG00000265179, ENSG00000256218, and LOC105377276—fulfilled three of the four criteria. Conclusions: We have systematically identified candidate PCOS regulatory lncRNAs with convergent genetic, expression, and evolutionary evidence. These results provide a framework for functional validation and highlight lncRNAs as potential biomarkers and therapeutic targets in PCOS that function by regulating their nearby and overlapping protein-coding genes.
Open AccessIntegrative Identification and Characterization of PCOS-Associated lncRNAs From the Interface of Genetic Association, Transcriptomics, and Gene Structure Evolution
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder and a leading cause of female infertility, with complex genetic, metabolic, and hormonal etiologies. Long non-coding RNAs (lncRNAs) have emerged as important regulators of diverse biological processes, yet their roles in PCOS remain underexplored. Here, we identified and characterized PCOS differentially expressed gene-associated lncRNAs (PDEGAL) with an integrative approach combining expression data, genetic association, and evolutionary analysis. Methods: Thirty-three PCOS-associated protein-coding genes were obtained from our prior study, and all their nearby and overlapping lncRNAs were annotated. These candidates were analyzed using UCSC Genome Browser-mapped annotations and datasets, including NCBI RefSeq, GENCODE, GTEx, GWAS SNPs, and conservation, as well as the FANTOM5 cap analysis of gene expression (CAGE) promoter data, to assess their expression, regulatory potential, genetic variant overlaps, and evolutionary conservation. Results: Twenty-three PDEGALs (18 antisense to, and 5 sharing bidirectional promoters with, known PCOS-associated protein-coding genes) were identified. 17 PDEGALs contained GWAS SNPs with statistically significant disease associations, 9 of which were associated with PCOS-related traits. 5 PDEGALs demonstrated expression in the KGN granulosa cell model of PCOS. Key gene structure element (KGSE) analysis revealed that most PDEGALs are primate-specific. Integrating four criteria—GTEx expression, GWAS SNPs, FANTOM promoterome, and KGSE conservation—highlighted HELLPAR as the only lncRNA fulfilling all four, while five others—PGR-AS1, MTOR-AS1, ENSG00000265179, ENSG00000256218, and LOC105377276—fulfilled three of the four criteria. Conclusions: We have systematically identified candidate PCOS regulatory lncRNAs with convergent genetic, expression, and evolutionary evidence. These results provide a framework for functional validation and highlight lncRNAs as potential biomarkers and therapeutic targets in PCOS that function by regulating their nearby and overlapping protein-coding genes.